We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Teva Announces FDA Acceptance of NDA for SD-809 for Huntington Disease Treatment

News   Aug 17, 2015

 
Teva Announces FDA Acceptance of NDA for SD-809 for Huntington Disease Treatment
 
 
Advertisement
 

RELATED ARTICLES

Expert Panel Makes Weak Recommendation for Use of Remdesivir To Treat Severe COVID-19

News

International experts have made a weak recommendation for the use of remdesivir in patients with severe COVID-19, advising continuation of patient enrolment for ongoing clinical trials of remdesivir to enable the collection of additional data.

READ MORE

Botox Injections May Reduce Depression

News

Researchers have mined the U.S. Food and Drug Administration’s Adverse Effect Reporting System (FAERS) database and have discovered that people who received Botox injections reported depression significantly less often than those undergoing alternative treatments for the same condition.

READ MORE

Pan-Bcl-2 and Bcl-xL-Specific Inhibitors: Adverse Effects From Cancer Drug Trials Explained

News

A certain type of cancer drug, known as pan-Bcl-2 or Bcl-xL-specific inhibitors, that promote the apotosis can actually be harmful if combined with other treatments that damage our DNA, RNA or proteins, researchers have found.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE